Best Practices and Research Advances in Thoracic Oncology: A Regional Series LATAM Course 3: Driver Alterations in Lung Cancer-Targeted Therapies in Advanced Disease and Brain Metastasis in Driver Alterations

Video Transcription

Video Summary

The video discusses advancements in targeted therapies for advanced non-small cell lung cancer, particularly in the context of brain metastasis and genetic mutations typical in Latin American populations. Initially, it explores the distinct genetic makeup of Latin America, noting variations in EGFR, KRAS, ALK, and other driver mutations among countries with different ancestral influences.<br /><br />Key breakthroughs include the development and efficacy of tyrosine kinase inhibitors (TKIs), focusing on first-generation to third-generation TKIs like Osimertinib. Osimertinib is highlighted for its strong CNS activity and better tolerance but faces resistance issues over time, prompting exploration of fourth-generation TKIs and liquid biopsies for ongoing evaluation.<br /><br />Recent studies, including the FLAURA and MARIPOSA trials, compared combinations of targeted therapies and chemotherapy, illustrating varying efficacy and challenges with toxicity. Emphasis is placed on meticulous patient selection due to toxicity risks in trials.<br /><br />The presentation highlights critical distinctions in treatment for various mutations, like ROS1, RET, MET 14 skipping mutations, and KRAS. The summary underscores the need for improved molecular testing, access to therapies, and inclusion of diverse populations in trials to enhance treatment strategies in Latin America, a region with distinct genetic and demographic profiles.

Asset Subtitle

Monica Castro, MD

Keywords

targeted therapies

non-small cell lung cancer

genetic mutations

tyrosine kinase inhibitors

Osimertinib

Latin American populations

molecular testing